Abstract:Zika virus (ZIKV) infection remains a serious health threat due to its close association with congenital Zika syndrome (CZS), which includes microcephaly and other severe birth defects. As no vaccines are available for human use, continuous effort is needed to develop effective and safe vaccines to prevent ZIKV infection. In this study, we constructed three recombinant proteins comprising, respectively, residues 296-406 (E296-406), 298-409 (E298-409), and 301-404 (E301-404) of ZIKV envelope (E) protein domain III (EDIII) fused with a C-terminal Fc of human IgG. Our results demonstrated that E298-409 induced the highest titer of neutralizing antibodies against infection with nine ZIKV strains isolated from different hosts, countries, and time periods, and it maintained long-term anti-ZIKV immunogenicity to induce neutralizing antibodies. Pups born to mice immunized with E298-409 were fully protected against lethal challenge with two epidemic human ZIKV strains, 2015/Honduras (R103451) and 2015/Colombia (FLR). Passive transfer of anti-E298-409 mouse sera protected pups born to naive mice, as well as type I interferon receptor-deficient adult A129 mice, from lethal challenge with human ZIKV strains R103451 and FLR, and this protection was positively correlated with neutralizing antibodies. These data suggest that the critical neutralizing fragment (i.e., a fragment that can induce highly potent neutralizing antibodies against divergent ZIKV strains) of ZIKV EDIII is a good candidate for development as an effective and safe ZIKV subunit vaccine to protect pregnant mothers and their fetuses against ZIKV infection. The E298-409-specific antibodies can be used for passive immunization to prevent ZIKV infection in newborns or immunocompromised adults.

Monoclonal Antibodies Against Zika Virus NS1 Protein Confer Protection Via Fcγ Receptor-Dependent and -Independent Pathways.

Monoclonal Antibodies against Zika Virus NS1 Protein Confer Protection via Fc γ Receptor-Dependent and -Independent Pathways

Antibodies targeting epitopes on the cell-surface form of NS1 protect against Zika virus infection during pregnancy

Molecular Determinants of Human Neutralizing Antibodies Isolated from a Patient Infected with Zika Virus.

A Single Injection of Human Neutralizing Antibody Protects Against Zika Virus Infection and Microcephaly in Developing Mouse Embryos.

The Zika virus NS1 protein as a vaccine target

Novel Non-Segmented Negative-Sense Rna Virus-Based Vaccine Platforms For Zika Virus

Protective threshold of a potent neutralizing Zika virus monoclonal antibody in rhesus macaques

Characterization of Two Highly Specific Monoclonal Antibodies Targeting the Glycan Loop of the Zika Virus Envelope Protein

Zika-specific neutralizing antibodies targeting inter-dimer envelope epitopes

A Zika Vaccine Targeting NS1 Protein Protects Immunocompetent Adult Mice in a Lethal Challenge Model

Neutralization of Zika Virus by Germline-Like Human Monoclonal Antibodies Targeting Cryptic Epitopes on Envelope Domain III

Potential Protective Effect of Dengue NS1 Human Monoclonal Antibodies against Dengue and Zika Virus Infections

Structural Basis for Neutralization and Protection by a Zika Virus-Specific Human Antibody

Specificity, cross-reactivity, and function of antibodies elicited by Zika virus infection

Critical Neutralizing Fragment Of Zika Virus Ediii Elicits Cross-Neutralization And Protection Against Divergent Zika Viruses

Antiviral Agents in Development for Zika Virus Infections

Longitudinal Analysis of the Antibody Repertoire of a Zika Virus-Infected Patient Revealed Dynamic Changes in Antibody Response

Delineating Antibody Recognition Against Zika Virus During Natural Infection.

Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys

Existing drugs as broad-spectrum and potent inhibitors for Zika virus by targeting NS2B-NS3 interaction